Ignyte Acquisition Corp
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with cancer, inflammatory, and rare diseases in the United States. The company's lead product candidate is PHP-303, which is in Phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an… Read more
Ignyte Acquisition Corp (PKBO) - Total Liabilities
Latest total liabilities as of September 2024: $22.54 Million USD
Based on the latest financial reports, Ignyte Acquisition Corp (PKBO) has total liabilities worth $22.54 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ignyte Acquisition Corp - Total Liabilities Trend (2020–2023)
This chart illustrates how Ignyte Acquisition Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ignyte Acquisition Corp Competitors by Total Liabilities
The table below lists competitors of Ignyte Acquisition Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Latitude Tree Holdings Bhd
KLSE:7006
|
Malaysia | RM140.25 Million |
|
WaterBridge Infrastructure LLC
NYSE:WBI
|
USA | $2.08 Billion |
|
MANPOWER (MPW.SG)
STU:MPW
|
Germany | €6.31 Billion |
|
HHLA N (HHFA.SG)
STU:HHFA
|
Germany | €2.23 Billion |
|
Brenmiller Energy Ltd Ordinary Shares
NASDAQ:BNRG
|
USA | $8.15 Million |
Liability Composition Analysis (2020–2023)
This chart breaks down Ignyte Acquisition Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 13.78 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ignyte Acquisition Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ignyte Acquisition Corp (2020–2023)
The table below shows the annual total liabilities of Ignyte Acquisition Corp from 2020 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $20.75 Million | +32.83% |
| 2022-12-31 | $15.62 Million | +418.47% |
| 2021-12-31 | $3.01 Million | +1804621.52% |
| 2020-12-31 | $166.98 | -- |